Monno S, Newman M V, Cook M, Lowe W L
Center for Endocrinology, Metabolism, and Molecular Medicine, Department of Medicine, Veterans Administration Chicago Healthcare System-Lakeside Division and Northwestern University Medical School, Illinois 60611, USA.
Endocrinology. 2000 Feb;141(2):544-50. doi: 10.1210/endo.141.2.7307.
Insulin-like growth factor I (IGF-I) is an important mediator of breast cancer cell growth, although the signaling pathways important for IGF-I-mediated effects in breast cancer cells are still being elucidated. We had demonstrated previously that increased intracellular cAMP in MCF-7 breast cancer cells inhibited cell growth and IGF-I-induced gene expression, as determined using a reporter gene assay. This effect of cAMP on IGF-I signaling was independent of IGF-I-induced activation of the mitogen-activated protein kinases extracellular signal-regulated kinases 1 and 2 (ERK1 and -2). To determine whether this effect of cAMP may be mediated via another mitogen-activated protein kinase, the ability of IGF-I to activate the c-Jun N-terminal kinases (JNKs) was investigated. Treatment of MCF-7 cells with 100 ng/ml IGF-I increased the level of phosphorylated JNK, as determined by Western blot analysis. JNK phosphorylation was not evident until 15 min after treatment with IGF-I, and peak levels of phosphorylation were present at 30-60 min. This was in contrast to ERK phosphorylation, which was present within 7.5 min of IGF-I treatment. Determination of JNK activity using an immune complex assay demonstrated a 3.3- and 3.5-fold increase in JNK1 and -2 activity, respectively, 30 min after treatment with 100 ng/ml IGF-I. The use of PD98059, which inhibits activation of ERK1 and -2, and LY 294002, an inhibitor of phosphatidylinositol 3-kinase, demonstrated that IGF-I-induced activation of JNK1 is independent of ERK and phosphatidylinositol 3-kinase activation. In contrast, increasing intracellular cAMP with forskolin resulted in abrogation of IGF-I-induced JNK activity. In summary, these data demonstrate that IGF-I activates the JNKs in MCF-7 breast cancer cells and, taken together with the results of our previous study, suggest that JNK may contribute to IGF-I-mediated gene expression and, possibly, cell growth in MCF-7 breast cancer cells.
胰岛素样生长因子I(IGF-I)是乳腺癌细胞生长的重要介质,尽管对IGF-I介导乳腺癌细胞效应的信号通路仍在阐明之中。我们之前已经证明,如使用报告基因检测所确定的,MCF-7乳腺癌细胞中细胞内cAMP增加会抑制细胞生长和IGF-I诱导的基因表达。cAMP对IGF-I信号传导的这种作用独立于IGF-I诱导的丝裂原活化蛋白激酶细胞外信号调节激酶1和2(ERK1和-2)的激活。为了确定cAMP的这种作用是否可能通过另一种丝裂原活化蛋白激酶介导,研究了IGF-I激活c-Jun氨基末端激酶(JNK)的能力。用100 ng/ml IGF-I处理MCF-7细胞,通过蛋白质印迹分析确定,磷酸化JNK水平增加。在用IGF-I处理15分钟后JNK磷酸化才明显,磷酸化峰值水平出现在30 - 60分钟。这与ERK磷酸化形成对比,ERK磷酸化在IGF-I处理7.5分钟内就出现。使用抑制ERK1和-2激活的PD98059以及磷脂酰肌醇3激酶抑制剂LY 294002表明,IGF-I诱导的JNK1激活独立于ERK和磷脂酰肌醇3激酶激活。相反,用福斯可林增加细胞内cAMP导致IGF-I诱导的JNK活性消失。总之,这些数据表明IGF-I在MCF-7乳腺癌细胞中激活JNK,结合我们之前研究的结果表明,JNK可能有助于IGF-I介导的基因表达,并且可能有助于MCF-7乳腺癌细胞的生长。